This is one of the most frequently asked questions we receive when we talk to companies, investors and VCs in the life sciences industry alike.
Often big pharma companies have a different approach to that used by companies starting out on their capital-raising journey and understanding the methods and principles of the different valuation strategies can be overwhelming. To shed some light on the mysteries around valuing life sciences companies, we have built a detailed guide on The Valuation of Biosciences Companies, which is free and available to download.
Comments